Cdk4 (N-Term) Mouse anti-Human, Unlabeled, Clone: DCS-35, BD

Description

• Cyclins, cyclin-dependent kinases (Cdks), and cyclin-dependent kinase inhibitors (CdkIs) are essential for cell-cycle control in eukaryotes (reviewed in 1)
• Cyclins, regulatory subunits, bind to cyclin-dependent kinases (Cdks), catalytic subunits, to form active cyclin-Cdk complexes
• Cdk subunits by themselves are inactive and binding to a cyclin is required for their activity
• Cyclins A, B1, D and E undergo periodic synthesis and degradation, thereby providing a mechanism to regulate Cdk activity throughout the cell cycle
• Additionally, Cdk activity is further regulated by activating and inhibitory phosphorylations, and small proteins (p15, p16, p18, p19, p21 and p27), called CdkIs, that bind to cyclins, Cdks, or cyclin-Cdk complexes
• Cdk4 was originally called PSK-J3,2 and following demonstration of its association with D-type cyclins, became known as Cdk4.2 D-type cyclins also associate with Cdks 2 and 5, although Cdk4 appears to be the most abundant partner
• The D-type cyclins (D1, D2, and D3) are expressed in response to growth factors or mitogens, and rapidly degrade when mitogens are withdrawn
• D cyclins appear to promote G0 to G1 transitions and the rate of G1 progression
• For example, cyclin D-Cdk4 and cyclin D-Cdk6 complexes phosphorylate the retinoblastoma protein (Rb) which removes the G1 phase block caused by underphosphorylated Rb
• Cdk4 has a molecular weight of ∽32kDa
• This antibody is routinely tested by western blot and bioimaging analysis
• Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature
• Immunofluorescence, Immunoprecipitation, Western Blotting